SOX9 and prostate cancer: Evidence showed that the WNT/β-catenin signaling is activated in prostate cancer cells, especially those with SOX9 overexpression, indicating that prostate cancer patients with high SOX9 levels are more sensitive to WNT pathway antagonists [163].